Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    September 2023
  1. MOLINA E, Garcia-Gutierrez L, Junco V, Perez-Olivares M, et al
    MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells.
    Oncogene. 2023 Sep 29. doi: 10.1038/s41388-023-02846.
    PubMed     Abstract available


    August 2023
  2. DIEPSTRATEN ST, La Marca JE, Chang C, Young S, et al
    BCL-W makes only minor contributions to MYC-driven lymphoma development.
    Oncogene. 2023 Aug 11. doi: 10.1038/s41388-023-02804.
    PubMed     Abstract available


    June 2023
  3. ZHAO S, Li J, Xia Q, Liu K, et al
    New perspectives for targeting therapy in ALK-positive human cancers.
    Oncogene. 2023;42:1959-1969.
    PubMed     Abstract available


    May 2023
  4. ZHENG J, Wang Z, Pan X, Zhang Z, et al
    DNMT3A(R882H) accelerates angioimmunoblastic T-cell lymphoma in mice.
    Oncogene. 2023 May 1. doi: 10.1038/s41388-023-02699.
    PubMed     Abstract available


    February 2023
  5. WU W, Lu P, Patel P, Ma J, et al
    SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.
    Oncogene. 2023;42:409-420.
    PubMed     Abstract available


    September 2022
  6. WINKLER R, Magdefrau AS, Piskor EM, Kleemann M, et al
    Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.
    Oncogene. 2022 Sep 6. pii: 10.1038/s41388-022-02450.
    PubMed     Abstract available


    June 2022
  7. HANG X, Zhao L, Wu B, Li S, et al
    BCL-2 isoform beta promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma.
    Oncogene. 2022 Jun 14. pii: 10.1038/s41388-022-02372.
    PubMed     Abstract available


    March 2022
  8. SUN R, Lei C, Chen L, He L, et al
    Alcohol-driven metabolic reprogramming promotes development of RORgammat-deficient thymic lymphoma.
    Oncogene. 2022 Mar 4. pii: 10.1038/s41388-022-02257.
    PubMed     Abstract available


    January 2022
  9. FIDYT K, Pastorczak A, Cyran J, Crump NT, et al
    Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.
    Oncogene. 2022 Jan 28. pii: 10.1038/s41388-022-02196.
    PubMed     Abstract available


    November 2021
  10. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    PubMed     Abstract available


  11. BERDITCHEVSKI F, Fennell E, Murray PG
    Calcium-dependent signalling in B-cell lymphomas.
    Oncogene. 2021;40:6321-6328.
    PubMed     Abstract available


  12. TU R, Kang W, Yang M, Wang L, et al
    USP29 coordinates MYC and HIF1alpha stabilization to promote tumor metabolism and progression.
    Oncogene. 2021;40:6417-6429.
    PubMed     Abstract available


    May 2021
  13. KUNOU S, Shimada K, Takai M, Sakamoto A, et al
    Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.
    Oncogene. 2021 May 16. pii: 10.1038/s41388-021-01829.
    PubMed     Abstract available


    April 2021
  14. ZHAO LN, Bjorklund M, Caldez MJ, Zheng J, et al
    Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential.
    Oncogene. 2021;40:2339-2354.
    PubMed     Abstract available


    March 2021
  15. AHMED SF, Buetow L, Gabrielsen M, Lilla S, et al
    E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Oncogene. 2021;40:2149-2164.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.